Abbott announced results from the Beta-CORRECT study showing its Oncodetect test, using whole-genome sequencing, improves detection of molecular residual disease (MRD) in colorectal cancer patients after surgery. The test showed a 30% higher sensitivity than previous methods, identifying patients with a 10.6-fold increased risk of cancer recurrence within two years. This advancement helps doctors better assess recurrence risk and tailor post-surgery treatment. Further research will explore how MRD testing can guide patient management over time.
Abbott's new data on its Oncodetect test highlights ongoing innovation in the health sector. On Pluang, Abbott Laboratories (ABT) shares trade at USD 102.03, down 0.47% as of Oct 23, 2026 20:32 WIB. The stock shows a dividend yield of 2.46% and a market cap of $177.38 billion, with most Pluang users (79%) buying rather than selling at this time.
Abbott Laboratories announced plans to spin off its Nutrition division to concentrate on higher-growth areas like diagnostics, medical devices, and pharmaceuticals. The company reported a 14.5% increase in Q3 revenue to $13.01 billion, driven mainly ...
Abbott Laboratories reported Q3 2026 results with adjusted earnings per share of $1.42, matching estimates, and revenue of $13.01 billion, slightly above expectations. Despite 14.5% sales growth, the company lowered its 2026 sales growth forecast due...
Abbott posted a 14.5% increase in reported sales and 7.0% comparable sales growth for Q3 2026, with GAAP diluted EPS of $0.53 and adjusted EPS of $1.42. The company expanded its portfolio with FDA approvals for innovative products like the Libre Duo ...
Abbott announced plans to separate its Nutrition business into a standalone, publicly traded company by the end of 2027. The new Nutrition company will focus on the growing healthy nutrition market with $8.5 billion in annual sales and iconic brands ...
